MCID: ART140
MIFTS: 52

Arteries, Anomalies of

Categories: Cardiovascular diseases

Aliases & Classifications for Arteries, Anomalies of

MalaCards integrated aliases for Arteries, Anomalies of:

Name: Arteries, Anomalies of 57
Artery Disease 12 15
Arteriopathic Disease 70

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant


HPO:

31
arteries, anomalies of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050828
OMIM® 57 108000
MedGen 41 C1876179
SNOMED-CT via HPO 68 263681008 49601007
UMLS 70 C0852949

Summaries for Arteries, Anomalies of

Disease Ontology : 12 A vascular disease that is located in an artery.

MalaCards based summary : Arteries, Anomalies of, also known as artery disease, is related to lipoprotein quantitative trait locus and carotid artery disease. An important gene associated with Arteries, Anomalies of is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Irbesartan and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include an artery, heart and endothelial, and related phenotype is abnormality of the cardiovascular system.

More information from OMIM: 108000

Related Diseases for Arteries, Anomalies of

Diseases related to Arteries, Anomalies of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1121)
# Related Disease Score Top Affiliating Genes
1 lipoprotein quantitative trait locus 34.0 SERPINA3 REN MIR590 MIR499A MIR423 MIR34A
2 carotid artery disease 33.4 REN MIR126 ACE
3 pulmonary artery disease 32.9 SERPINA3 MIR126 ACE
4 vascular disease 32.9 REN MIR221 MIR21 MIR199A1 MIR146A MIR143
5 myocardial infarction 32.8 SERPINA3 REN MIR499A MIR423 MIR34A MIR221
6 arteriosclerosis 32.6 MIR21 MIR142 MIR133A1 MIR126 ACE
7 heart disease 32.6 REN MIR590 MIR499A MIR423 MIR24-1 MIR21
8 intermediate coronary syndrome 32.6 REN MIR423 MIR142 MIR126 ACE
9 aortic disease 32.4 SERPINA3 REN MIR423 MIR21 MIR199A1 MIR17
10 cardiovascular system disease 32.3 SERPINA3 REN MIR590 MIR499A MIR423 MIR34A
11 kidney disease 32.1 SERPINA3 REN MIR21 MIR199A1 MIR17 MIR126
12 acute myocardial infarction 32.1 SERPINA3 MIR499A MIR423 MIR34A MIR21 MIR199A1
13 cerebrovascular disease 32.1 SERPINA3 REN MIR21 MIR199A1 ACE
14 chronic kidney disease 32.0 SERPINA3 REN MIR21 MIR126 ACE
15 aortic aneurysm, familial abdominal, 1 31.9 SERPINA3 REN MIR199A1 MIR126 ACE
16 heart valve disease 31.9 SERPINA3 REN MIR499A MIR423 MIR21 MIR199A1
17 mitral valve insufficiency 31.8 REN MIR423 ACE
18 pulmonary disease, chronic obstructive 31.8 SERPINA3 MIR423 MIR21 MIR199A1 MIR17 MIR142
19 hypertension, essential 31.7 SERPINA3 REN MIR590 MIR423 MIR33A MIR24-1
20 aortic valve disease 2 31.6 SERPINA3 REN MIR590 MIR423 MIR34A MIR21
21 body mass index quantitative trait locus 11 31.6 SERPINA3 REN MIR423 MIR34A MIR221 MIR21
22 non-alcoholic fatty liver disease 31.5 MIR34A MIR33A MIR21 MIR199A1 MIR17 MIR126
23 aortic valve disease 1 31.5 REN MIR21 MIR199A1 MIR17 ACE
24 microvascular complications of diabetes 3 31.5 REN MIR21 ACE
25 periodontitis 31.4 SERPINA3 MIR21 MIR146A
26 microvascular complications of diabetes 5 31.4 MIR21 MIR126 H2AC18 ACE
27 heart septal defect 31.4 MIR499A MIR423 MIR199A1 MIR17 H2AC18
28 mitral valve stenosis 31.4 SERPINA3 REN ACE
29 mitral valve disease 31.4 SERPINA3 REN MIR423 ACE
30 psoriasis 31.4 MIR21 MIR17 MIR146A MIR142 CCR6 ACE
31 mental depression 31.3 SERPINA3 MIR24-1 H2AC18 CCR6
32 immune deficiency disease 31.3 SERPINA3 MIR34A MIR24-1 MIR21 MIR199A1 MIR17
33 systemic lupus erythematosus 31.2 MIR423 MIR21 MIR146A MIR142 H2AC18 CCR6
34 orthostatic intolerance 31.2 REN MIR423 ACE
35 sexual disorder 31.1 REN H2AC18 ACE
36 retinal vascular disease 31.1 REN MIR21 MIR199A1 MIR17 MIR126 H2AC18
37 lung cancer 31.1 SERPINA3 MIR590 MIR499A MIR423 MIR34A MIR33A
38 generalized atherosclerosis 31.1 REN ACE
39 systemic scleroderma 31.0 MIR142 H2AC18 CCR6 ACE
40 respiratory failure 31.0 SERPINA3 REN MIR126 H2AC18 CCR6 ACE
41 peripheral nervous system disease 31.0 SERPINA3 MIR590 MIR423 MIR34A MIR24-1 MIR21
42 anterolateral myocardial infarction 31.0 MIR142 ACE
43 pulmonary fibrosis, idiopathic 31.0 MIR21 MIR199A1 MIR142 CCR6 ACE
44 disease of mental health 30.9 SERPINA3 REN MIR590 MIR423 MIR34A MIR24-1
45 connective tissue disease 30.9 SERPINA3 MIR590 MIR423 MIR34A MIR24-1 MIR221
46 diastolic heart failure 30.9 REN MIR499A ACE
47 substance abuse 30.8 SERPINA3 MIR199A1 H2AC18 CCR6 ACE
48 leukemia, chronic myeloid 30.8 MIR199A1 MIR17 MIR142 MIR126 H2AC18
49 colorectal cancer 30.8 SERPINA3 MIR34A MIR24-1 MIR221 MIR21 MIR199A1
50 placenta disease 30.8 SERPINA3 REN MIR199A1 MIR146A H2AC18

Graphical network of the top 20 diseases related to Arteries, Anomalies of:



Diseases related to Arteries, Anomalies of

Symptoms & Phenotypes for Arteries, Anomalies of

Human phenotypes related to Arteries, Anomalies of:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 31 HP:0001626

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Vascular:
abnormal radial, ulnar, or interosseous artery

Clinical features from OMIM®:

108000 (Updated 05-Apr-2021)

Drugs & Therapeutics for Arteries, Anomalies of

Drugs for Arteries, Anomalies of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 649)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
2
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
3
Esmolol Approved Phase 4 103598-03-4, 81147-92-4 59768
4
Glycolic acid Approved, Investigational Phase 4 79-14-1 757
5
Nicardipine Approved, Investigational Phase 4 55985-32-5 4474
6
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
7
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
8
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
9
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
10
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
11
Probucol Approved, Investigational Phase 4 23288-49-5 4912
12
Ticlopidine Approved Phase 4 55142-85-3 5472
13
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
14
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
15
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
16
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
17
Ramipril Approved Phase 4 87333-19-5 5362129
18
Pravastatin Approved Phase 4 81093-37-0 54687
19
Cangrelor Approved Phase 4 163706-06-7 9854012
20
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
21
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
22
Insulin glargine Approved Phase 4 160337-95-1
23
Eplerenone Approved Phase 4 107724-20-9 443872 150310
24
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
25
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
26
Iodine Approved, Investigational Phase 4 7553-56-2 807
27
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
28
Linagliptin Approved Phase 4 668270-12-0 10096344
29
Allopurinol Approved Phase 4 315-30-0 2094
30
Polyestradiol phosphate Approved Phase 4 28014-46-2
31
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
32
Glyburide Approved Phase 4 10238-21-8 3488
33
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
34
Insulin aspart Approved Phase 4 116094-23-6 16132418
35
Abciximab Approved Phase 4 143653-53-6
36
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
37
Fenofibrate Approved Phase 4 49562-28-9 3339
38
Etomidate Approved Phase 4 33125-97-2 36339 667484
39
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
40
Thiopental Approved, Vet_approved Phase 4 76-75-5 3000715
41
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
42
Ranitidine Approved, Withdrawn Phase 4 66357-35-5, 66357-59-3, 82530-72-1 3001055
43
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
44
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
45
Cosyntropin Approved Phase 4 16960-16-0 16129617
46
Glimepiride Approved Phase 4 93479-97-1 3476
47
Methylnaltrexone Approved Phase 4 916055-93-1, 83387-25-1 6603824
48
Remifentanil Approved Phase 4 132875-61-7 60815
49
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
50
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966

Interventional clinical trials:

(show top 50) (show all 5169)
# Name Status NCT ID Phase Drugs
1 Comparison of the Everolimus Eluting (XIENCE-V®, XIENCE-Prime® or PROMUS® Stent) With the Biolimus A9 Eluting NOBORI® Stent in All-comers: a Randomized Open Label Study Unknown status NCT01233453 Phase 4
2 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
3 A Multi Center Registry to Evaluate Multiple Stenting Using by Everolimus-eluting Stents for Treatment of Long Coronary Artery Disease Unknown status NCT01147237 Phase 4
4 Assessment of Surface Coverage of Polymer-based Sirolimus-eluting Stent( Cypher ) or Polymer-free Paclitaxel-eluting Stent (YinYi )in Diabetes Mellitus and Non- Diabetes Mellitus Patients by Optical Coherence Tomography Unknown status NCT01023919 Phase 4
5 Renoprotection by Combining Pentoxifylline and Angiotensin Blockade in Chronic Kidney Disease Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
6 Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound Unknown status NCT03529253 Phase 4 Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily;Rosuvastatin calcium10mg
7 Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
8 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
9 Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial) Unknown status NCT02501616 Phase 4 Metformin;Dapagliflozin
10 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
11 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
12 A Randomized, Double-Blind, Placebo-Controlled Trial for DaZhu Rhodiola Rosea Capsule in the Treatment of Coronary Artery Disease With Angina Pectoris Unknown status NCT03633890 Phase 4 DaZhu Rhodiola Rosea Capsule;DaZhu Rhodiola Rosea Simulation Capsule
13 Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease Unknown status NCT00986752 Phase 4
14 Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
15 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients (Age > 75 Years Old) With Coronary Artery Disease: a Randomized Controlled Study Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
16 Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS) Unknown status NCT01083394 Phase 4
17 Healthy Heart Study: Can Insulin Glargine Improve Myocardial Function in Patients With Type 2 Diabetes and Coronary Artery Disease? A Prospective, Randomized, Controlled Clinical Study With Blinded Analysis of Ultrasound Data Unknown status NCT01035528 Phase 4 insulin glargine;metformin
18 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
19 Evaluation of the Strategy of "One-stop" Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease Unknown status NCT03563768 Phase 4
20 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
21 Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study Unknown status NCT03360981 Phase 4 Incretins
22 Diagnostic Value of a Rapid Protocol Regadenoson Stress Cardiovascular Magnetic Resonance Scan for Detection of Coronary Artery Disease Unknown status NCT01446094 Phase 4 regadenoson
23 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
24 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
25 Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
26 Comparison of the Pharmacodynamic Effects of RanOlazine Versus aMlodipine on Platelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual ANtiplatelet Therapy - The ROMAN Randomized Study Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
27 Peripheral Artery Disease in Patients on Maintenance Hemodialysis: Risk Factors and the Effect of FIR Therapy Unknown status NCT01095549 Phase 4
28 Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study Unknown status NCT03700645 Phase 4 Allopurinol
29 Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study Unknown status NCT03679091 Phase 4 low-dose ticagrelor;Clopidogrel
30 Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease Unknown status NCT01418794 Phase 4
31 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Unknown status NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
32 Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
33 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
34 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT)-A Randomized Controlled Trial Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
35 The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
36 Multicenter, Randomized, Non-inferiority Study of Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
37 The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
38 Clinical Evaluation of the Momo Cobalt-Chromium Coronary Stent System for the Treatment of Patients With Coronary Artery Disease Unknown status NCT01535625 Phase 4
39 Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
40 Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography. Unknown status NCT02874287 Phase 4 Hydroxychloroquine Sulfate Tablets;Placebo Tablets
41 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
42 Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management. Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
43 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
44 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
45 Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
46 Randomized Placebo-controlled Crossover Trial of Endothelial Function Improvement in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
47 Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease Unknown status NCT03398577 Phase 4 Dapagliflozin 10 MG [Farxiga];Placebo Oral Tablet
48 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
49 Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) Unknown status NCT03277079 Phase 4 statin + ezetimibe;statin + ezetimibe + Nutraceuticals
50 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel

Search NIH Clinical Center for Arteries, Anomalies of

Genetic Tests for Arteries, Anomalies of

Anatomical Context for Arteries, Anomalies of

The Foundational Model of Anatomy Ontology organs/tissues related to Arteries, Anomalies of:

19
An Artery

MalaCards organs/tissues related to Arteries, Anomalies of:

40
Heart, Endothelial, Kidney, Bone, Bone Marrow, Liver, Lung

Publications for Arteries, Anomalies of

Articles related to Arteries, Anomalies of:

(show top 50) (show all 30005)
# Title Authors PMID Year
1
Outcome of acute myocardial infarction versus stable coronary artery disease patients treated with coronary bypass surgery. 61
32875916 2021
2
Diastolic dysfunction in women with ischemia and no obstructive coronary artery disease: Mechanistic insight from magnetic resonance imaging. 61
33545261 2021
3
Morning blood pressure surge is associated with the severity of stable coronary artery disease in hypertensive patients. 61
33576694 2021
4
Impaired activity of circulating EPCs and endothelial function are associated with increased Syntax score in patients with coronary artery disease. 61
33760184 2021
5
Prognostic value of asymmetric dimethylarginine in patients with coronary artery disease: A meta-analysis. 61
33684543 2021
6
Is there an optimal dose of cardiac rehabilitation in coronary artery disease patients? 61
33545262 2021
7
Variability in utilization of diagnostic imaging tests in patients with symptomatic peripheral artery disease. 61
33581177 2021
8
Ticagrelor Does Not Protect Against Endothelial Ischemia-Reperfusion Injury in Patients With Coronary Artery Disease. 61
33094636 2021
9
Serum Uric Acid Levels, but Not rs7442295 Polymorphism of SCL2A9 Gene, Predict Mortality in Clinically Stable Coronary Artery Disease. 61
33540324 2021
10
A plasma lipid signature predicts incident coronary artery disease. 61
33545264 2021
11
Klotho, FOXO1 and cytokines associations in patients with coronary artery disease. 61
33582500 2021
12
Association of vaspin rs2236242 gene variants and circulating serum vaspin concentrations with coronary artery disease in a Turkish population. 61
33078402 2021
13
The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. 61
32891803 2021
14
Associations between smoking habits and major adverse cardiovascular events in patients who underwent coronary computed tomography angiography as screening for coronary artery disease. 61
33245490 2021
15
Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. 61
33385541 2021
16
Circulating microRNA-126 &122 in patients with coronary artery disease: Correlation with small dense LDL. 61
33556577 2021
17
MALAT1/miRNA-203/Wnt5a: A potential mechanism for regulating coronary artery disease. 61
33358830 2021
18
Lessons learned from an attempted randomized-controlled feasibility trial on "WIDeCAD" - An internet-based depression treatment for people living with coronary artery disease (CAD). 61
33732627 2021
19
In-Hospital Outcomes and Trends of Endovascular Intervention vs Surgical Revascularization in Octogenarians With Peripheral Artery Disease. 61
33460607 2021
20
Comparison of Outcomes of Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Among Patients With Three-Vessel Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From CREDO-Kyoto PCI/CABG Registry Cohort-3). 61
33454340 2021
21
The Society for Vascular Surgery Alternative Payment Model Task Force report on opportunities for value-based reimbursement in care for patients with peripheral artery disease. 61
32931874 2021
22
A Brave New World: Toward Precision Phenotyping and Understanding of Coronary Artery Disease Using Radiomics Plaque Analysis. 61
33595391 2021
23
A clinical strategy to improve the diagnostic accuracy of 1.5-T non-contrast MR coronary angiography for detection of coronary artery disease: combination of whole-heart and volume-targeted imaging. 61
32975662 2021
24
Peripheral artery disease and clinical outcomes in patients with atrial fibrillation: A report from the FANTASIIA registry. 61
33065765 2021
25
Nerve growth factor in muscle afferent neurons of peripheral artery disease and autonomic function. 61
33063730 2021
26
Automatic text-mining as an unbiased approach to uncover molecular associations between periodontitis and coronary artery disease. 61
33736543 2021
27
Improved risk assessment of coronary artery disease by substituting paraoxonase 1 activity for HDL-C: Novel cardiometabolic biomarkers based on HDL functionality. 61
33579580 2021
28
Erratum. Coronary Artery Disease and Type 2 Diabetes: A Proteomic Study. Diabetes Care 2020;43:843-851. 61
33483359 2021
29
Effectiveness and safety of dual-layer stents in carotid artery disease: a systematic review. 61
33337115 2021
30
Revascularization or medical therapy for stable coronary artery disease: To do or not to do, that is the question. 61
33358836 2021
31
Aortic Distensibility Can Predict Events in Patients With Premature Coronary Artery Disease: A Cardiac Magnetic Resonance Study. 61
33191760 2021
32
Causal effects of dietary calcium, zinc and iron intakes on coronary artery disease in men: G-estimation and inverse probability of treatment weighting (IPTW) analyses. 61
33745624 2021
33
Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes. 61
33787603 2021
34
Prevention of Coronary Artery Disease-Related Heart Failure: The Role of Computed Tomography Scan. 61
33673944 2021
35
Differentially expressed miR-152, a potential biomarker for in-stent restenosis (ISR) in peripheral blood mononuclear cells (PBMCs) of coronary artery disease (CAD) patients. 61
33712363 2021
36
Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. 61
33558267 2021
37
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graftinge Among Patients with Unprotected Left Main Coronary Artery Disease in the New-Generation Drug-Eluting Stents Era (From the CREDO-Kyoto PCI/CABG Registry Cohort-3). 61
33454345 2021
38
A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. 61
33161072 2021
39
Carotid Atherosclerosis in Predicting Coronary Artery Disease: A Systematic Review and Meta-Analysis. 61
33626907 2021
40
Consumption of potatoes and incidence rate of coronary artery disease: The Million Veteran Program. 61
33745578 2021
41
Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease. 61
33657880 2021
42
The Utility of Peripheral Intravascular Lithotripsy in Calcific Coronary Artery Disease: A Case Series. 61
33723088 2021
43
The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance. 61
33724726 2021
44
Association Between Plasma ADAMTS-9 Levels and Severity of Coronary Artery Disease. 61
33307720 2021
45
Multiparametric exercise stress cardiovascular magnetic resonance in the diagnosis of coronary artery disease: the EMPIRE trial. 61
33658056 2021
46
Microcrystalline paclitaxel-coated balloon for revascularization of femoropopliteal artery disease: Three-year outcomes of the randomized BIOPAC trial. 61
33686879 2021
47
Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. 61
33710385 2021
48
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology. 61
32846201 2021
49
Cardiac rehabilitation in women; comparison of enrollment, adherence and outcomes between heart failure and coronary artery disease. 61
33340824 2021
50
Prevalence of the Academic Research Consortium high bleeding risk criteria in patients undergoing endovascular therapy for peripheral artery disease in lower extremities. 61
33651134 2021

Variations for Arteries, Anomalies of

Expression for Arteries, Anomalies of

Search GEO for disease gene expression data for Arteries, Anomalies of.

Pathways for Arteries, Anomalies of

Pathways related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.81 MIR423 MIR34A MIR221 MIR21 MIR199A1 MIR17

GO Terms for Arteries, Anomalies of

Cellular components related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 SERPINA3 MIR423 MIR34A MIR24-1 MIR21 MIR17
2 extracellular space GO:0005615 9.5 SERPINA3 REN MIR590 MIR423 MIR24-1 MIR221
3 extracellular vesicle GO:1903561 9.43 MIR34A MIR24-1 MIR221 MIR21 MIR17 MIR126

Biological processes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 39)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.95 MIR34A MIR33A MIR21 MIR17 MIR146A ACE
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.94 MIR24-1 MIR221 MIR21 MIR126
3 positive regulation of angiogenesis GO:0045766 9.91 MIR21 MIR199A1 MIR143 MIR126
4 negative regulation of cell migration GO:0030336 9.91 MIR34A MIR21 MIR133A1 MIR126
5 positive regulation of protein kinase B signaling GO:0051897 9.89 MIR221 MIR21 MIR199A1 MIR143 MIR126
6 cellular response to hypoxia GO:0071456 9.86 MIR34A MIR17 MIR146A MIR126
7 negative regulation of ERK1 and ERK2 cascade GO:0070373 9.83 MIR221 MIR21 MIR133A1
8 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.8 MIR221 MIR199A1 MIR146A
9 negative regulation of inflammatory response GO:0050728 9.8 MIR590 MIR221 MIR146A MIR142 MIR126
10 negative regulation of angiogenesis GO:0016525 9.77 MIR34A MIR24-1 MIR21 MIR146A MIR143
11 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR499A MIR221 MIR21 MIR17
12 negative regulation of NIK/NF-kappaB signaling GO:1901223 9.75 MIR590 MIR21 MIR146A
13 negative regulation of sprouting angiogenesis GO:1903671 9.74 MIR34A MIR221 MIR17
14 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR499A MIR221 MIR143 MIR126
15 negative regulation of vascular endothelial cell proliferation GO:1905563 9.72 MIR34A MIR24-1 MIR126
16 positive regulation of vascular endothelial cell proliferation GO:1905564 9.71 MIR499A MIR21 MIR126
17 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.7 MIR21 MIR146A MIR126
18 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.69 MIR199A1 MIR17 MIR133A1
19 cell growth involved in cardiac muscle cell development GO:0061049 9.68 MIR24-1 MIR199A1
20 negative regulation of cell adhesion molecule production GO:0060354 9.68 MIR221 MIR146A
21 positive regulation of connective tissue replacement GO:1905205 9.67 MIR34A MIR199A1
22 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.67 MIR17 MIR133A1
23 amyloid-beta metabolic process GO:0050435 9.67 REN ACE
24 negative regulation of matrix metallopeptidase secretion GO:1904465 9.66 MIR199A1 MIR146A
25 angiotensin maturation GO:0002003 9.66 REN ACE
26 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.65 MIR199A1 MIR17
27 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.65 MIR221 MIR146A
28 positive regulation of metalloendopeptidase activity GO:1904685 9.64 MIR21 MIR17
29 negative regulation of myoblast proliferation GO:2000818 9.63 MIR499A MIR133A1
30 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
31 miRNA mediated inhibition of translation GO:0035278 9.63 MIR590 MIR499A MIR221 MIR21 MIR17 MIR146A
32 negative regulation of interleukin-21 production GO:0032705 9.62 MIR221 MIR21
33 negative regulation of vascular endothelial growth factor production GO:1904046 9.62 MIR34A MIR199A1 MIR17 MIR146A
34 positive regulation of cardiac muscle tissue regeneration GO:1905180 9.6 MIR590 MIR199A1
35 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.59 MIR17 MIR143
36 negative regulation of intracellular signal transduction GO:1902532 9.58 MIR34A MIR146A
37 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.56 MIR499A MIR221 MIR21 MIR143
38 gene silencing by miRNA GO:0035195 9.5 MIR590 MIR499A MIR423 MIR34A MIR33A MIR24-1
39 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.35 MIR590 MIR24-1 MIR21 MIR199A1 MIR133A1

Molecular functions related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.56 MIR34A MIR24-1 MIR21 MIR17 MIR146A MIR143
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR590 MIR499A MIR423 MIR34A MIR33A MIR24-1

Sources for Arteries, Anomalies of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....